Global DNA Encoded Library Market (2nd Edition) — Industry Trends and Global Forecast, Till 2035

GLOBAL DNA ENCODED LIBRARY MARKET OVERVIEW

The global DNA encoded library market is projected to grow from USD 1.3 billion in the current year to USD 5.0 billion by 2035, representing a CAGR of 16.3% during the forecast period.

DNA Encoded Library Market: Growth and Trends

DNA encoded libraries (DELs) have emerged as an efficient drug discovery platform, enabling the synthesis and screening of millions to trillions of small molecule compounds in a single study. By using unique DNA sequences as molecular barcodes, DEL technology enables rapid compound identification following pooled screening, helping pharmaceutical and biotechnology companies accelerate discovery while reducing screening time and costs.

Growing demand for novel therapies for complex diseases, particularly oncology and neurological disorders, is driving investment in DEL platforms. Adoption has expanded across pharmaceutical and biotechnology companies, academic institutions, and contract research organizations, strengthening the role of DELs across the drug discovery value chain. Leading pharmaceutical companies, including Amgen, GSK, Pfizer, Roche, Novartis, AstraZeneca, Bristol Myers Squibb, Sanofi, and Janssen, have adopted DEL technology through internal programs or external collaborations.

Strategic partnerships, licensing agreements, and acquisitions continue to shape the competitive landscape. More than 175 strategic partnerships have been established in the DEL space since 2010, covering platform licensing, research and development, and product development. Recent activities include collaborations between Orbit Discovery and SanegeneBio and the acquisition of Glamorous.AI by X-Chem to strengthen artificial intelligence capabilities.

Investment activity has also increased, reflecting growing confidence in DEL-based drug discovery. DEL-focused companies have attracted substantial funding through venture financing and other investment rounds, while cumulative investment has expanded significantly in recent years. Patent activity has similarly increased, highlighting continued innovation across DEL technologies, screening platforms, and related applications.

The integration of artificial intelligence and machine learning is further expanding DEL capabilities by enabling more efficient analysis of large chemical spaces and improving hit identification and optimization. Strategic acquisitions and collaborations involving companies such as Insitro, X-Chem, and Relay Therapeutics demonstrate the growing convergence of DEL technology with AI-driven drug discovery.

Growth Drivers for the DNA Encoded Library Market

The global DNA encoded library market is driven by the technology’s ability to accelerate drug discovery while reducing screening time and costs compared with traditional methods. Growing demand for innovative therapies targeting oncology, neurological disorders, and other complex diseases is further supporting adoption. Increasing integration of DEL platforms by pharmaceutical companies, clinical advancement of DEL-derived candidates, and growing applications of artificial intelligence and machine learning are strengthening market potential. Additionally, sustained venture capital investment and strategic partnerships are supporting platform innovation and commercialization.

Market Challenges: Factors Impeding Market Growth

The DNA encoded library market faces challenges related to a limited provider base, evolving commercial models, and the technical complexity of library design and screening. Limited availability of specialized providers may create capacity constraints as demand increases, while reliance on licensing and fee-for-service models can create revenue uncertainty for emerging companies. High technical requirements across library construction, DNA encoding, chemistry, and sequencing also increase development complexity. In addition, continued dependence on venture funding may create financial pressure for early-stage DEL companies.

Opportunity Areas in the DNA Encoded Library Market

Several emerging avenues offer meaningful upside across the DNA encoded library value chain:

Screening Against Undruggable Targets: DEL's demonstrated ability to identify leads against previously undruggable and unique targets positions it as a differentiated tool for hard-to-treat disease areas.
Advanced Peptide and Macrocycle Libraries: BioDuro's disclosure of a 108-channel automated synthesis platform capable of constructing billion-scale DNA-encoded peptide libraries with 10-mer-plus macrocycles at approximately 90% crude purity points to a widening application of DEL technology beyond small molecules.
Antiviral and Non-Classical Target Discovery: Dual DEL selection strategy identified the first covalent allosteric inhibitors of SARS-CoV-2 RdRp, demonstrating DEL's capability to uncover non-classical druggable sites relevant to antiviral drug development.
Expansion Beyond Drug Discovery: X-Chem's collaboration with Enko to enhance the Enkompass platform for crop protection illustrates how DEL technology is finding application outside conventional pharmaceutical discovery.

DNA Encoded Library Market: Key Insights

Close to 50 large, mid-sized and small companies currently offer DNA encoded library services spanning hit identification, hit optimization and validation, and lead generation.
Around 70% of these companies provide some form of library screening service.
Nearly 403 patents have been filed in the field of DNA encoded libraries. Of these, 277 patents are patent applications, while 114 are granted patents. Of the total granted patents, around 65% patents have been filed in the US.
Big pharma involvement remains a defining feature of the competitive landscape, with Amgen operating its DEL platform in-house following its acquisition of Nuevolution, alongside other major players engaging through collaboration models.
As confidence in DEL-based drug discovery grows, these models are expected to become increasingly collaborative in nature.

Recent Developments Signaling Market Momentum

BioDuro announced a 108-channel automated synthesis platform enabling construction of DNA-encoded peptide libraries with 10-mer-plus macrocycles, achieving approximately 90% crude purity and supporting billion-scale libraries.
Researchers reported a dual DNA-encoded library selection strategy that identified the first covalent allosteric inhibitors of SARS-CoV-2 RdRp, with low-micromolar potency against a novel binding pocket.
Orbit Discovery and SanegeneBio entered a research agreement to identify and optimize hits targeting a disease-causing gene.

DNA Encoded Library Market Segments

The report segments the global DNA encoded library market across the following parameters:

By Application Area

Hit Generation / Identification
Hit to Lead
Hit Validation / Optimization
Other Application Areas

By Therapeutic Area

Oncological Disorders
Immunological Disorders
Neurological Disorders
Respiratory Disorders
Dermatological Disorders
Cardiovascular Disorders
Infectious Diseases
Other Therapeutic Areas

By End-User

Pharma / Biopharma Industry
Academic / Research Institute
Other End-Users

By Type of Payment Model Employed

Upfront Payment
Milestone Payment

By Key Geographical Regions

North America (US)
Europe (UK, Germany, Denmark, France, Switzerland, Rest of Europe)
Asia-Pacific (China)

DNA Encoded Library Market: Key Segment Insights

Hit Discovery Drives DEL Adoption

Hit generation and identification holds the highest share of the market. This dominance is supported by the ability of DEL technology to screen extensive compound libraries efficiently and accelerate early-stage drug discovery.

Oncology Leads Therapeutic Applications

Oncology holds the highest share, driven by strong demand for novel small molecule and macrocycle candidates targeting cancer-related pathways. Growing applications in infectious diseases and other therapeutic areas are further broadening DEL adoption.

Pharma and Biotech Companies Lead End-User Demand

Pharmaceutical and biotechnology companies hold the highest share among end users, supported by increasing integration of DEL platforms into drug discovery programs. Providers are also adopting more collaborative and milestone-based payment models alongside traditional upfront and fee-based arrangements.

North America Leads the Global Market

North America holds the highest share, supported by the presence of established DEL providers, major pharmaceutical companies, strong research capabilities, and investment activity. Europe also represents a key regional market, supported by a growing concentration of DEL companies and research programs.

Example Players in DNA Encoded Library Market

BOC Sciences
DyNAbind
Edelris
GenScript
HitGen
NovAliX
PROVendis
SpiroChem
Vipergen
WuXi AppTec
X-Chem

DNA ENCODED LIBRARY MARKET RESEARCH COVERAGE

Market Forecast and Opportunity Analysis: Quantitative assessment of the global DNA encoded library market, including historical trends, future forecasts and scenario analysis across application areas, therapeutic areas, end users, payment models and key geographical regions.
Competitive Landscape Analysis: Detailed evaluation of DNA encoded library platform and service providers based on company size, year of establishment, headquarters, organization type, library size, synthesis methods, screening methods, products, services, pharmacological leads, therapeutic targets, therapeutic areas and end users.
Company Competitiveness Analysis: Comparative assessment of leading platform and service providers based on business models, product and service portfolios, platforms, pharmacological leads, therapeutic areas and therapeutic targets.
Company Profiles: Detailed profiles of prominent DNA encoded library platform and service providers, covering company overview, management, platform and service portfolios, recent developments and future outlook.
Partnerships and Collaborations: Analysis of strategic agreements across research, R&D, technology and product licensing, product development, commercialization, mergers and acquisitions, and other collaboration models.
Funding and Investments: Evaluation of investments made in DNA encoded library companies, including venture capital financing, IPOs and subsequent offerings, grants and debt financing, with analysis of funding activity and investor participation.
Patent Analysis: In-depth assessment of the DNA encoded library patent landscape, including patent applications and grants, publication and application years, jurisdictions, CPC classifications, leading patent holders, organization type, patent benchmarking and patent valuation.
Big Pharma Initiatives: Assessment of DNA encoded library-related initiatives undertaken by leading pharmaceutical companies, including strategic adoption, collaborations and other activities across the industry.
Supporting Ecosystem Analysis: Analysis of companies and organizations supporting DNA encoded library development through building blocks, oligos, scaffolds and other ancillary tools and services.
Strategic Insights: Analysis of key winning strategies and the evolving commercial opportunities for DNA encoded library platform and service providers.

KEY QUESTIONS ANSWERED

What is a DNA encoded library, and how does it accelerate drug discovery?
How big is the global DNA encoded library market today, and what is its projected size through 2035?
What CAGR is the DNA encoded library market expected to register over the forecast period?
What are the primary growth drivers and restraints shaping the DNA encoded library industry?
Which application area and therapeutic area hold the largest share of the market today?
Which region leads the global DNA encoded library market, and which regions are expected to dominate by 2035?
Who are the leading DNA encoded library platform and service providers?

REASONS TO BUY THIS REPORT

Gain a comprehensive, ten-year forecast of the global DNA encoded library market segmented across five distinct parameters.
Identify high-growth application and therapeutic areas, including infectious disease and non-classical target discovery, ahead of broader market recognition.
Benchmark competitive positioning across close to 50 DEL platform and service providers and big pharma in-house programs.
Track recent partnerships, acquisitions, funding rounds and patent activity shaping the competitive landscape.
Support investment, partnership and business development decisions with region- and segment-level market sizing data.

ADDITIONAL BENEFITS

Complementary PPT Insights Pack
Complementary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated Report if the Report is 6-12 Months Old or Older

1. PREFACE

1.1. DNA Encoded Library Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA Encoded Library Screening
3.3.4. Lead Generation
3.3.5. Lead Optimization
3.4. Overview of DNA Encoded Libraries
3.4.1. Encoding Strategies for Library Construction
3.4.2. Historical Evolution of DNA Encoded Libraries
3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
3.4.4. Key Advantages of DNA Encoded Libraries
3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries
3.5. Future Perspectives and Opportunity Areas

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Company / Organization
4.2.6. Analysis by Library Size
4.2.7. Analysis by Library Synthesis Method(s)
4.2.8. Analysis by Library Screening Method(s)
4.2.9. Analysis by Type of Product(s) Offered
4.2.10. Analysis by Type of Service(s) Offered
4.2.10.1. Analysis by Type of Library Design Service(s) Offered
4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
4.2.11. Analysis by Type of Pharmacological Lead(s)
4.2.12. Analysis by Therapeutic Target(s)
4.2.13. Analysis by Therapeutic Area(s)
4.2.14. Analysis by End-user(s)

5. BUSINESS MODEL ANALYSIS

5.1. Chapter Overview
5.2. DNA Encoded Library Companies: Business Model Analysis
5.2.1. Analysis by Operational Model
5.2.1.1. Analysis by Company Size and Operational Model
5.2.1.2. Analysis by Location of Headquarters and Operational Model
5.2.2. Analysis by Business Model
5.2.2.1. Analysis by Service Centric Model
5.2.2.2. Analysis by Product Centric Model
5.3. Concluding Remarks

6. COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
6.4.1. DNA Encoded Library Companies based in North America
6.4.2. DNA Encoded Library Companies based in Europe
6.4.3. DNA Encoded Library Companies based in Asia-Pacific

7. COMPANY PROFILES

7.1. Chapter Overview
7.2. AlphaMa
7.2.1. Company Overview
7.2.2. DNA Encoded Library Platform and Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DICE Therapeutics
7.3.1. Company Overview
7.3.2. DNA Encoded Library Platform and Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. DyNAbind
7.4.1. Company Overview
7.4.2. DNA Encoded Library Platform and Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. HitGen
7.5.1. Company Overview
7.5.2. DNA Encoded Library Platform and Service Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. NovAliX
7.6.1. Company Overview
7.6.2. DNA Encoded Library Platform and Service Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Vipergen
7.7.1. Company Overview
7.7.2. DNA Encoded Library Platform and Service Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. WuXi AppTec
7.8.1. Company Overview
7.8.2. DNA Encoded Library Platform and Service Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. X-Chem
7.9.1. Company Overview
7.9.2. DNA Encoded Library Platform and Service Portfolio
7.9.3. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Encoded Libraries: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Type of Partner
8.3.6.1 Analysis by Partner Company Size
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. International and Local Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Encoded Libraries: Funding and Investment Analysis
9.3.1. Analysis of Instances by Year of Funding
9.3.2. Analysis of Amount Invested by Year of Funding
9.3.3. Analysis of Instances by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Most Active Players: Analysis by Amount Raised
9.3.7. Most Active Investors: Analysis by Number of Instances
9.3.8. Analysis by Geography
9.3.9. Concluding Remarks

10. PATENT ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. DNA Encoded Libraries: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Type of Patent and Publication Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. DNA Encoded Libraries: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. BIG PHARMA INITIATIVES

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
11.4. Benchmark Analysis of Big Pharma Players
11.4.1. Spider Web Analysis: AbbVie
11.4.2. Spider Web Analysis: Amgen
11.4.3. Spider Web Analysis: AstraZeneca
11.4.4. Spider Web Analysis: Bayer
11.4.5. Spider Web Analysis: Boehringer Ingelheim
11.4.6. Spider Web Analysis: Eli Lilly
11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
11.4.8. Spider Web Analysis: Johnson & Johnson
11.4.9. Spider Web Analysis: Merck
11.4.10. Spider Web Analysis: Novartis
11.4.11. Spider Web Analysis: Pfizer
11.4.12. Spider Web Analysis: Sanofi
11.5. Concluding Remarks

12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES

12.1. Chapter Overview
12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters
12.2.4. Analysis by Company Size and Location of Headquarters
12.2.5. Analysis by Type of Company / Organization
12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035
13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035
13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035
13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035
13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035
13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035
13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS

15.1. Chapter Overview
15.2. Vipergen
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer
15.3. Serengen
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer
15.4. Deluge Biotechnologies
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President
15.5. NovAliX
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development
15.6. Orbit Discovery
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist
15.7. Anonymous

16. APPENDIX 1: TABULATED DATA17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

Table 4.1 DNA Encoded Libraries: List of Service Providers / Platform Providers / In-House Companies
Table 4.2 DNA Encoded Libraries: Information on Library Size, Library Synthesis Method(s) and Library Screening Method(s)
Table 4.3 DNA Encoded Libraries: Information on Type of Product(s) and Service(s) Offered
Table 4.4 DNA Encoded Libraries: Information on Type of Pharmacological Lead(s) and Therapeutic Target(s)
Table 4.5 DNA Encoded Libraries: Information on Therapeutic Area(s) and End-user(s)
Table 5.1 DNA Encoded Libraries: Information on Company Size, Location of Headquarters and Operational Model
Table 5.2 DNA Encoded Libraries: Information on Business Model
Table 7.1 DNA Encoded Libraries: List of Companies Profiled
Table 7.2 AlphaMa: Company Snapshot
Table 7.3 AlphaMa: DNA Encoded Library Platform and Service Portfolio
Table 7.4 AlphaMa: Recent Developments and Future Outlook
Table 7.5 DICE Therapeutics: Company Snapshot
Table 7.6 DICE Therapeutics: DNA Encoded Library Platform and Service Portfolio
Table 7.7 DICE Therapeutics: Recent Developments and Future Outlook
Table 7.8 DyNAbind: Company Snapshot
Table 7.9 DyNAbind: DNA Encoded Library Platform and Service Portfolio
Table 7.10 DyNAbind: Recent Developments and Future Outlook
Table 7.11 HitGen: Company Snapshot
Table 7.12 HitGen: DNA Encoded Library Platform and Service Portfolio
Table 7.13 HitGen: Recent Developments and Future Outlook
Table 7.14 NovAliX: Company Snapshot
Table 7.15 NovAliX: DNA Encoded Library Platform and Service Portfolio
Table 7.16 NovAliX: Recent Developments and Future Outlook
Table 7.17 Vipergen: Company Snapshot
Table 7.18 Vipergen: DNA Encoded Library Platform and Service Portfolio
Table 7.19 Vipergen: Recent Developments and Future Outlook
Table 7.20 WuXi AppTec: Company Snapshot
Table 7.21 WuXi AppTec: DNA Encoded Library Platform and Service Portfolio
Table 7.22 X-Chem: Company Snapshot
Table 7.23 X-Chem: DNA Encoded Library Platform and Service Portfolio
Table 7.24 X-Chem: Recent Developments and Future Outlook
Table 8.1 DNA Encoded Libraries: List of Partnerships and Collaborations, 2010-2023
Table 9.1 DNA Encoded Libraries: List of Funding and Investments, 2018-2023
Table 10.1 Patent Analysis: Top CPC Sections
Table 10.2 Patent Analysis: Top CPC Symbols
Table 10.3 Patent Analysis: Top CPC Codes
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 12.1 DNA Encoded Libraries: List of Supporting Companies / Organizations
Table 12.2 DNA Encoded Libraries: Information on Type of Support Services / Ancillary Tools Offered
Table 13.1 DNA Encoded Libraries: Average Upfront Payment and Average Milestone Payment, 2016-2022 (USD Million)
Table 13.2 Library Licensing Deals: Tranches of Milestone Payments
Table 15.1 Vipergen: Company Key Highlights
Table 15.2 Serengen: Company Key Highlights
Table 15.3 Deluge Biotechnologies: Company Key Highlights
Table 15.4 NovAliX: Company Key Highlights
Table 15.5 Orbit Discovery: Company Key Highlights
Table 16.1 DNA Encoded Libraries: Distribution by Year of Establishment
Table 16.2 DNA Encoded Libraries: Distribution by Company Size
Table 16.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
Table 16.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
Table 16.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
Table 16.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
Table 16.7 DNA Encoded Libraries: Distribution by Library Size
Table 16.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
Table 16.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
Table 16.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
Table 16.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
Table 16.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
Table 16.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
Table 16.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
Table 16.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
Table 16.16 DNA Encoded Libraries: Distribution by End-user(s)
Table 16.17 DNA Encoded Libraries: Distribution by Operational Model
Table 16.18 DNA Encoded Libraries: Distribution by Company Size and Operational Model
Table 16.19 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
Table 16.20 DNA Encoded Libraries: Distribution by Business Model
Table 16.21 DNA Encoded Libraries: Distribution by Service Centric Model
Table 16.22 DNA Encoded Libraries: Distribution by Product Centric Model
Table 16.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
Table 16.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.26 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
Table 16.27 Partnerships and Collaborations: Distribution by Focus Area
Table 16.28 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.29 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.30 Partnerships and Collaborations: Distribution by Partner Company Size
Table 16.31 Most Active Players: Distribution by Number of Partnerships
Table 16.32 Partnerships and Collaborations: International and Local Agreements
Table 16.33 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.34 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
Table 16.35 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
Table 16.36 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
Table 16.37 Funding and Investment: Distribution of Instances by Type of Funding
Table 16.38 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
Table 16.39 Most Active Players: Distribution by Number of Funding Instances
Table 16.40 Most Active Players: Distribution by Amount Raised (USD Million)
Table 16.41 Most Active Investors: Distribution by Number of Instances
Table 16.42 Funding and Investment Analysis: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
Table 16.43 Funding and Investment Analysis: Distribution of Number of Instances by Geography (Country-wise)
Table 16.44 Funding and Investment Analysis: Summary of Investments by Number of Instances and Amount Invested (USD Million)
Table 16.45 Patent Analysis: Distribution by Type of Patent
Table 16.46 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
Table 16.47 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
Table 16.48 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
Table 16.49 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Table 16.50 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Table 16.51 Patent Analysis: Distribution by CPC Symbols
Table 16.52 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.53 Leading Industry Players: Distribution by Number of Patents
Table 16.54 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.55 Leading Individual Assignees: Distribution by Number of Patents
Table 16.56 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 16.57 Patent Analysis: Distribution by Patent Age
Table 16.58 Patent Analysis: Distribution by Relative Patent Valuation
Table 16.59 Big Pharma Players: Heat Map Analysis of Top Pharma Companies
Table 16.60 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
Table 16.61 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
Table 16.62 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
Table 16.63 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
Table 16.64 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
Table 16.65 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
Table 16.66 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
Table 16.67 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Opportunity, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
Table 16.68 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
Table 16.69 DNA Encoded Library Market for Hit Generation / Identification, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.70 DNA Encoded Library Market for Hit to Lead, Conservative, Base and Optimistic Scenarios, 2023-2035(USD Million)
Table 16.71 DNA Encoded Library Market for Hit Validation / Optimization, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.72 DNA Encoded Library Market for Other Application Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.73 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Table 16.74 DNA Encoded Library Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.75 DNA Encoded Library Market for Immunological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.76 DNA Encoded Library Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.77 DNA Encoded Library Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.78 DNA Encoded Library Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.79 DNA Encoded Library Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.80 DNA Encoded Library Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.81 DNA Encoded Library Market for Other Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.82 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
Table 16.83 DNA Encoded Library Market for Pharma / Biopharma Industry, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.84 DNA Encoded Library Market for Academic / Research Institute, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.85 DNA Encoded Library Market for Other End-users, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.86 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
Table 16.87 DNA Encoded Library Market: Upfront Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.88 DNA Encoded Library Market: Milestone Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.89 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 16.90 DNA Encoded Library Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.91 DNA Encoded Library Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.92 DNA Encoded Library Market in Denmark, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.93 DNA Encoded Library Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.94 DNA Encoded Library Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.95 DNA Encoded Library Market in Switzerland, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.96 DNA Encoded Library Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.97 DNA Encoded Library Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.98 DNA Encoded Library Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)

List of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Business Model Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Construction Process of a DNA Encoded Library
Figure 3.4 Encoding Strategies for Constructing DNA Encoded Libraries
Figure 3.5 Historical Evolution of DNA Encoded Libraries
Figure 3.6 Comparison of Traditional Libraries and DNA Encoded Libraries
Figure 3.7 Key Advantages of DNA Encoded Libraries
Figure 3.8 Challenges and Limitations Associated with DNA Encoded Libraries
Figure 4.1 DNA Encoded Libraries: Distribution by Year of Establishment
Figure 4.2 DNA Encoded Libraries: Distribution by Company Size
Figure 4.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
Figure 4.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
Figure 4.7 DNA Encoded Libraries: Distribution by Library Size
Figure 4.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
Figure 4.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
Figure 4.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
Figure 4.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
Figure 4.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
Figure 4.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
Figure 4.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
Figure 4.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
Figure 4.16 DNA Encoded Libraries: Distribution by End-user(s)
Figure 5.1 DNA Encoded Libraries: Distribution by Operational Model
Figure 5.2 DNA Encoded Libraries: Distribution by Company Size and Operational Model
Figure 5.3 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
Figure 5.4 DNA Encoded Libraries: Distribution by Business Model
Figure 5.5 DNA Encoded Libraries: Distribution by Service Centric Model
Figure 5.6 DNA Encoded Libraries: Distribution by Product Centric Model
Figure 6.1 Company Competitiveness Analysis: DNA Encoded Library Companies based in North America
Figure 6.2 Company Competitiveness Analysis: DNA Encoded Library Companies based in Europe
Figure 6.3 Company Competitiveness Analysis: DNA Encoded Library Companies based in Asia-Pacific
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
Figure 8.5 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8 Partnerships and Collaborations: Distribution by Partner Company Size
Figure 8.9 Most Active Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: International and Local Agreements
Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
Figure 9.2 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
Figure 9.3 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
Figure 9.4 Funding and Investment: Distribution of Instances by Type of Funding
Figure 9.5 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 9.8 Most Active Investors: Distribution by Number of Instances
Figure 9.9 Funding and Investment: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
Figure 9.10 Funding and Investment: Distribution of Number of Instances by Geography (Country-wise)
Figure 9.11 Funding and Investment: Summary of Investments by Number of Instances and Amount Invested (USD Million)
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
Figure 10.3 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
Figure 10.4 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Figure 10.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Figure 10.7 Patent Analysis: Distribution by CPC Symbols
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Patent Analysis: Distribution by Relative Patent Valuation
Figure 11.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharma Companies
Figure 11.2 Spider Web Analysis: AbbVie
Figure 11.3 Spider Web Analysis: Amgen
Figure 11.4 Spider Web Analysis: AstraZeneca
Figure 11.5 Spider Web Analysis: Bayer
Figure 11.6 Spider Web Analysis: Boehringer Ingelheim
Figure 11.7 Spider Web Analysis: Eli Lilly
Figure 11.8 Spider Web Analysis: GlaxoSmithKline (GSK)
Figure 11.9 Spider Web Analysis: Johnson & Johnson
Figure 11.10 Spider Web Analysis: Merck
Figure 11.11 Spider Web Analysis: Novartis
Figure 11.12 Spider Web Analysis: Pfizer
Figure 11.13 Spider Web Analysis: Sanofi
Figure 12.1 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
Figure 12.2 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
Figure 12.3 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
Figure 12.4 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
Figure 12.5 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
Figure 12.6 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
Figure 12.7 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035 (USD Billion)
Figure 13.4 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
Figure 13.5 DNA Encoded Library Market for Hit Generation / Identification, 2023-2035 (USD Million)
Figure 13.6 DNA Encoded Library Market for Hit to Lead, 2023-2035(USD Million)
Figure 13.7 DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035 (USD Million)
Figure 13.8 DNA Encoded Library Market for Other Application Areas, 2023-2035 (USD Million)
Figure 13.9 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 13.10 DNA Encoded Library Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 13.11 DNA Encoded Library Market for Immunological Disorders, 2023-2035 (USD Million)
Figure 13.12 DNA Encoded Library Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 13.13 DNA Encoded Library Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 13.14 DNA Encoded Library Market for Dermatological Disorders, 2023-2035 (USD Million)
Figure 13.15 DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 13.16 DNA Encoded Library Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 13.17 DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035 (USD Million)
Figure 13.18 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
Figure 13.19 DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035 (USD Million)
Figure 13.20 DNA Encoded Library Market for Academic / Research Institute, 2023-2035 (USD Million)
Figure 13.21 DNA Encoded Library Market for Other End-users, 2023-2035 (USD Million)
Figure 13.22 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
Figure 13.23 DNA Encoded Library Market: Upfront Payments, 2023-2035 (USD Million)
Figure 13.24 DNA Encoded Library Market: Milestone Payments, 2023-2035 (USD Million)
Figure 10.25 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 13.26 DNA Encoded Library Market in the US, 2023-2035 (USD Million)
Figure 13.27 DNA Encoded Library Market in Europe, 2023-2035 (USD Million)
Figure 13.28 DNA Encoded Library Market in Denmark, 2023-2035 (USD Million)
Figure 13.29 DNA Encoded Library Market in Germany, 2023-2035 (USD Million)
Figure 10.30 DNA Encoded Library Market in UK, 2023-2035 (USD Million)
Figure 13.31 DNA Encoded Library Market in Switzerland, 2023-2035 (USD Million)
Figure 13.32 DNA Encoded Library Market in France, 2023-2035 (USD Million)
Figure 13.33 DNA Encoded Library Market in Rest of the Europe, 2023-2035 (USD Million)
Figure 13.34 DNA Encoded Library Market in China, 2023-2035 (USD Million)
Figure 14.1 Concluding Remarks: Market Landscape
Figure 14.2 Concluding Remarks: Business Model Analysis
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Funding and Investment Analysis
Figure 14.5 Concluding Remarks: Patent Analysis
Figure 14.6 Concluding Remarks: Market Forecast and Opportunity Analysis

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

BOC Sciences
DyNAbind
Edelris
GenScript
HitGen
NovAliX
PROVendis
SpiroChem
Vipergen
WuXi AppTec
X-Chem

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4466EUR$4,799USD£3,735GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7445EUR$7,999USD£6,226GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16752EUR$17,999USD£14,009GBP